Do analysts rate NCYT or SPEC?

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 37.50%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts clearly believe INSPECS Group is more favorable than Novacyt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novacyt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, NCYT or SPEC?

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novacyt £20.03M 1.59 -£36.80M -£32.00 N/A INSPECS Group £191.70M 0.55 -£4.11M -£9.40 N/A

Is NCYT or SPEC more profitable?

INSPECS Group has a net margin of -0.52% compared to Novacyt's net margin of -103.08%. INSPECS Group's return on equity of -1.19% beat Novacyt's return on equity. Company Net Margins Return on Equity Return on Assets Novacyt -103.08% -96.44% -27.98% INSPECS Group -0.52% -1.19% 0.45%

Do analysts prefer EKF or NCYT?

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 37.54%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe EKF Diagnostics is more favorable than Novacyt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Novacyt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, EKF or NCYT?

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio EKF Diagnostics £51.56M 2.11 £4.68M £0.47 54.14 Novacyt £20.03M 1.59 -£36.80M -£32.00 N/A

Is EKF or NCYT more profitable?

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity. Company Net Margins Return on Equity Return on Assets EKF Diagnostics 4.12% 3.01% 5.27% Novacyt -103.08% -96.44% -27.98%

Novacyt (NCYT) Competitors

GBX 44 0.00 (0.00%)

As of 09/11/2026 12:44 PM Eastern

Compare

NCYT vs. SPEC, EKF, CREO, IUG, and BVC

Should you buy Novacyt stock or one of its competitors? Novacyt's main competitors and comparable companies include INSPECS Group (SPEC), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Novacyt compare to INSPECS Group?

Novacyt (LON:NCYT) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, INSPECS Group had 4 more articles in the media than Novacyt. MarketBeat recorded 4 mentions for INSPECS Group and 0 mentions for Novacyt. Novacyt's average media sentiment score of 0.00 beat INSPECS Group's score of -0.34 indicating that Novacyt is being referred to more favorably in the media.

Company	Overall Sentiment
Novacyt	Neutral
INSPECS Group	Neutral

10.7% of Novacyt shares are held by institutional investors. Comparatively, 0.2% of INSPECS Group shares are held by institutional investors. 0.4% of Novacyt shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 37.50%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts clearly believe INSPECS Group is more favorable than Novacyt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novacyt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Novacyt has a beta of 1.112, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, suggesting that its stock price is 60% more volatile than the broader market.

INSPECS Group has a net margin of -0.52% compared to Novacyt's net margin of -103.08%. INSPECS Group's return on equity of -1.19% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-103.08%	-96.44%	-27.98%
INSPECS Group	-0.52%	-1.19%	0.45%

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£20.03M	1.59	-£36.80M	-£32.00	N/A
INSPECS Group	£191.70M	0.55	-£4.11M	-£9.40	N/A

Summary

INSPECS Group beats Novacyt on 12 of the 16 factors compared between the two stocks.

How does Novacyt compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
Novacyt	-103.08%	-96.44%	-27.98%

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.11	£4.68M	£0.47	54.14
Novacyt	£20.03M	1.59	-£36.80M	-£32.00	N/A

EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market.

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 37.54%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe EKF Diagnostics is more favorable than Novacyt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Novacyt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Novacyt	Neutral

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 40.2% of EKF Diagnostics shares are owned by insiders. Comparatively, 0.4% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

EKF Diagnostics beats Novacyt on 13 of the 14 factors compared between the two stocks.

How does Novacyt compare to Creo Medical Group?

Novacyt (LON:NCYT) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Creo Medical Group has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£20.03M	1.59	-£36.80M	-£32.00	N/A
Creo Medical Group	£6M	10.12	-£25.04M	£1.00	12.50

10.7% of Novacyt shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 7.0% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -103.08%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-103.08%	-96.44%	-27.98%
Creo Medical Group	88.33%	9.56%	-20.09%

In the previous week, Novacyt's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Novacyt	Neutral
Creo Medical Group	Neutral

Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market.

Summary

Creo Medical Group beats Novacyt on 10 of the 11 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -103.08%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Ultrasound Group	-23.11%	-23.58%	-13.51%
Novacyt	-103.08%	-96.44%	-27.98%

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Ultrasound Group	£6.57M	0.00	-£2.27M	-£0.68	N/A
Novacyt	£20.03M	1.59	-£36.80M	-£32.00	N/A

In the previous week, Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company	Overall Sentiment
Intelligent Ultrasound Group	Neutral
Novacyt	Neutral

Intelligent Ultrasound Group has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, meaning that its share price is 11% more volatile than the broader market.

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 10 factors compared between the two stocks.

How does Novacyt compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

14.3% of BATM Advanced Communications shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 31.0% of BATM Advanced Communications shares are held by company insiders. Comparatively, 0.4% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BATM Advanced Communications has a beta of 0.754, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, suggesting that its stock price is 11% more volatile than the broader market.

BATM Advanced Communications has higher revenue and earnings than Novacyt. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BATM Advanced Communications	£104.57M	0.37	-£278.26K	-£3.94	N/A
Novacyt	£20.03M	1.59	-£36.80M	-£32.00	N/A

BATM Advanced Communications has a net margin of -15.91% compared to Novacyt's net margin of -103.08%. BATM Advanced Communications' return on equity of -25.90% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BATM Advanced Communications	-15.91%	-25.90%	0.58%
Novacyt	-103.08%	-96.44%	-27.98%

In the previous week, BATM Advanced Communications had 3 more articles in the media than Novacyt. MarketBeat recorded 3 mentions for BATM Advanced Communications and 0 mentions for Novacyt. BATM Advanced Communications' average media sentiment score of 0.56 beat Novacyt's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the media.

Company	Overall Sentiment
BATM Advanced Communications	Positive
Novacyt	Neutral

Summary

BATM Advanced Communications beats Novacyt on 10 of the 13 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCYT vs. The Competition

Export

Metric	Novacyt	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£31.53M	£5.48B	£7.16B	£2.51B
Dividend Yield	N/A	1.80%	2.57%	6.25%
P/E Ratio	-1.38	25.09	274.94	366.83
Price / Sales	1.59	71.54	685.44	89,753.13
Price / Cash	0.58	32.57	76.65	27.89
Price / Book	0.44	5.97	10.33	6.33
Net Income	-£36.80M	£150.75M	£3.50B	£5.89B
7 Day Performance	1.15%	-2.83%	-3.32%	-0.69%
1 Month Performance	-2.00%	-3.73%	-0.53%	0.00%
1 Year Performance	6.30%	9.38%	23.51%	19.96%

Novacyt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCYT Novacyt	N/A	GBX 44 flat	N/A	+6.3%	£31.53M	£20.03M	N/A	120
SPEC INSPECS Group	0.55 of 5 stars	GBX 100 +4.2%	GBX 60 -40.0%	N/A	£109.18M	£191.70M	N/A	1,673	News Coverage Earnings Report Gap Up
EKF EKF Diagnostics	N/A	GBX 25.49 +1.4%	GBX 35 +37.3%	-13.2%	£109.14M	£51.56M	54.23	356
CREO Creo Medical Group	N/A	GBX 12.75 +1.0%	GBX 40 +213.7%	+4.2%	£61.94M	£6M	12.75	279
IUG Intelligent Ultrasound Group	N/A	N/A	N/A	N/A	£42.76M	£6.57M	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novacyt (NCYT) Competitors

NCYT vs. SPEC, EKF, CREO, IUG, and BVC

How does Novacyt compare to INSPECS Group?

Summary

How does Novacyt compare to EKF Diagnostics?

Summary

How does Novacyt compare to Creo Medical Group?

Summary

How does Novacyt compare to Intelligent Ultrasound Group?

Summary

How does Novacyt compare to BATM Advanced Communications?

Summary

Media Sentiment Over Time

NCYT vs. The Competition

Novacyt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novacyt (NCYT) Competitors

NCYT vs. SPEC, EKF, CREO, IUG, and BVC

How does Novacyt compare to INSPECS Group?

Does the media favor NCYT or SPEC?

Do insiders & institutionals have more ownership in NCYT or SPEC?

Do analysts rate NCYT or SPEC?

Which has more volatility and risk, NCYT or SPEC?

Is NCYT or SPEC more profitable?

Which has preferable earnings and valuation, NCYT or SPEC?

Summary

How does Novacyt compare to EKF Diagnostics?

Is EKF or NCYT more profitable?

Which has higher earnings and valuation, EKF or NCYT?

Which has more risk & volatility, EKF or NCYT?

Do analysts prefer EKF or NCYT?

Does the media refer more to EKF or NCYT?

Do institutionals & insiders hold more shares of EKF or NCYT?

Summary

How does Novacyt compare to Creo Medical Group?

Which has stronger earnings and valuation, NCYT or CREO?

Do insiders and institutionals hold more shares of NCYT or CREO?

Is NCYT or CREO more profitable?

Does the media refer more to NCYT or CREO?

Which has more risk & volatility, NCYT or CREO?

Summary

How does Novacyt compare to Intelligent Ultrasound Group?

Do insiders & institutionals believe in IUG or NCYT?

Is IUG or NCYT more profitable?

Which has preferable earnings and valuation, IUG or NCYT?

Does the media prefer IUG or NCYT?

Which has more volatility & risk, IUG or NCYT?

Summary

How does Novacyt compare to BATM Advanced Communications?

Do institutionals & insiders have more ownership in BVC or NCYT?

Which has more volatility and risk, BVC or NCYT?

Which has higher earnings and valuation, BVC or NCYT?

Is BVC or NCYT more profitable?

Does the media refer more to BVC or NCYT?

Summary

Media Sentiment Over Time

NCYT vs. The Competition

Novacyt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools